发明名称 |
SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNF ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS |
摘要 |
<p>The invention provides tools for management of patients diagnosed with ankylosing spondylitis and prior to the initiation of therapy with an anti-TNFalpha agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary endpoints using serum marker concentrations. In one embodiment the baseline level of leptin or osteocalcin is used to predict the response at Week 14 after the intiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as complement component 3.</p> |
申请公布号 |
WO2010077722(A1) |
申请公布日期 |
2010.07.08 |
申请号 |
WO2009US67282 |
申请日期 |
2009.12.09 |
申请人 |
CENTOCOR ORTHO BIOTECH INC.;VISVANATHAN, SUDHA;WAGNER, CARRIE |
发明人 |
VISVANATHAN, SUDHA;WAGNER, CARRIE |
分类号 |
C12Q1/68 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|